Justin Smith
Stock Analyst at Bernstein
(4.07)
# 1,657
Out of 5,073 analysts
159
Total ratings
56.7%
Success rate
8.6%
Average return
Main Sectors:
Stocks Rated by Justin Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 20,200p → 19,800p | 12,614p | +56.97% | 37 | Oct 7, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 434.50 | CHF 392.00 | +10.84% | 27 | Oct 6, 2026 | |
| SWX: SFZN Siegfried Holding AG | Reiterated: Buy | n/a | $71.60 | - | 1 | Sep 14, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €112.00 → €151.00 | €142.25 | +6.15% | 2 | Aug 7, 2026 | |
| EPA: SAN Sanofi | Reiterated: Buy | €107.00 → €106.21 | €73.57 | +44.37% | 4 | Aug 4, 2026 | |
| LON: GSK GSK plc | Reiterated: Buy | 2,825p → 3,010p | 1,868p | +61.13% | 25 | Aug 3, 2026 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | n/a | $623.60 | - | 9 | Jul 24, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 125.00 → CHF 133.00 | CHF 126.88 | +4.82% | 2 | Jul 22, 2026 | |
| NVS Novartis AG | Initiated Coverage: Hold | n/a | $153.93 | - | 1 | Mar 19, 2026 | |
| GMAB Genmab | Reiterated: Sell | n/a | $39.57 | n/a | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $29.85 | n/a | 8 | Aug 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €10.50 → €2.90 | €0.76 | n/a | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 → €21.50 | €10.09 | n/a | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $85 → $51 | $61.12 | n/a | 10 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $104 | $149.88 | n/a | 4 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €45.80 → €71.00 | €38.45 | n/a | 7 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €69.00 → €70.00 | €45.60 | n/a | 6 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $59.11 | n/a | 2 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $172 → $140 | $284.80 | n/a | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $50.02 | n/a | 1 | Sep 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.86 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $21.56 | n/a | 1 | Feb 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $78 | $1,270.75 | n/a | 1 | Apr 7, 2016 |
AstraZeneca PLC
Oct 7, 2026
Reiterated: Buy
Price Target: 20,200p → 19,800p
Current: 12,614p
Upside: +56.97%
Roche Holding AG
Oct 6, 2026
Reiterated: Buy
Price Target: CHF 434.50
Current: CHF 392.00
Upside: +10.84%
Siegfried Holding AG
Sep 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $71.60
Upside: -
Merck KGaA
Aug 7, 2026
Reiterated: Hold
Price Target: €112.00 → €151.00
Current: €142.25
Upside: +6.15%
Sanofi
Aug 4, 2026
Reiterated: Buy
Price Target: €107.00 → €106.21
Current: €73.57
Upside: +44.37%
GSK plc
Aug 3, 2026
Reiterated: Buy
Price Target: 2,825p → 3,010p
Current: 1,868p
Upside: +61.13%
Lonza Group AG
Jul 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $623.60
Upside: -
Novartis AG
Jul 22, 2026
Rated: Hold
Price Target: CHF 125.00 → CHF 133.00
Current: CHF 126.88
Upside: +4.82%
Novartis AG
Mar 19, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $153.93
Upside: -
Genmab
Sep 8, 2025
Reiterated: Sell
Price Target: n/a
Current: $39.57
Upside: n/a
Aug 17, 2025
Reiterated: Hold
Price Target: n/a
Current: $29.85
Upside: n/a
Mar 31, 2025
Downgraded: Hold
Price Target: €10.50 → €2.90
Current: €0.76
Upside: n/a
Dec 10, 2024
Reiterated: Buy
Price Target: €22.00 → €21.50
Current: €10.09
Upside: n/a
Mar 11, 2024
Downgraded: Hold
Price Target: $85 → $51
Current: $61.12
Upside: n/a
Mar 11, 2024
Downgraded: Sell
Price Target: $104
Current: $149.88
Upside: n/a
Nov 17, 2023
Upgraded: Buy
Price Target: €45.80 → €71.00
Current: €38.45
Upside: n/a
Nov 17, 2023
Reiterated: Buy
Price Target: €69.00 → €70.00
Current: €45.60
Upside: n/a
Feb 27, 2023
Upgraded: Buy
Price Target: n/a
Current: $59.11
Upside: n/a
Nov 8, 2022
Downgraded: Hold
Price Target: $172 → $140
Current: $284.80
Upside: n/a
Sep 3, 2019
Upgraded: Buy
Price Target: n/a
Current: $50.02
Upside: n/a
Nov 12, 2018
Reiterated: Buy
Price Target: n/a
Current: $12.86
Upside: n/a
Feb 24, 2017
Downgraded: Hold
Price Target: n/a
Current: $21.56
Upside: n/a
Apr 7, 2016
Initiated Coverage: Hold
Price Target: $78
Current: $1,270.75
Upside: n/a